|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 26, 2015 ) The report “Herpes Zoster (Shingles) – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects.
Herpes Zoster (Shingles) is caused by the varicella-zoster virus, the same virus that causes chickenpox. The first symptom is usually pain, tingling, or burning that occurs on one side of the body. The pain and burning may be severe and are usually present before any rash appears. Almost 1 out of every 3 people in the United States will develop shingles. About half of all cases occur in men and women 60 years old or older.
Companies discussed in this Herpes Zoster (Shingles) – Pipeline Review, H1 2015 report include: Astellas Pharma Inc., Epiphany Biosciences, Inc., Foamix Pharmaceuticals Ltd., GlaxoSmithKline plc, Merck & Co., Inc., NAL Pharmaceuticals Ltd., Spider Biotech.
Drugs profiles discussed in this report includes acyclovir, amenamevir, FV-100, GSK-1437173A, NAL-3221, NAL-3223, SB105-A10, V-212, valomaciclovir stearate. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=365323 . (This is a premium report priced at US$2000 for a single user License.)
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Featured News & Press Releases cover by this report includes:
Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN; Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint; Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant; Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles; Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles; Apr 09, 2013: Zoster Vaccine Effective Against Incident Herpes Zoster And Post-herpetic Neuralgia In Older US Population, Cohort Study Finds; Jul 18, 2012: Agenus Annnounces Intiation Of Phase III Clinical Trial Of GSK's Herpes Zoster Vaccine Candidate In Immunocompromised Patients; Jun 05, 2012: Kaiser Permanente Study Shows GSK's Zoster Lowers Short-Term Risk Of Shingles Recurrence; Dec 13, 2010: Inhibitex Reports Promising Top-Line Results From Phase II Shingles Trial With FV-100; Oct 15, 2010: Inhibitex Completes Enrollment In Phase II Clinical Trial Of FV-100 In Shingles Patients.
Scope
• The report provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles)
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Herpes Zoster (Shingles) and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Herpes Zoster (Shingles) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Herpes Zoster (Shingles) pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Reasons to buy
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles)
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore more reports on Infectious Diseases Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .
RnR Market Research
Ritesh Tiwari
+18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
